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Abstract
Background: Association between celiac disease and type 1 diabetes in adults is still somewhat unclear, and that
between celiac disease and type 2 diabetes even less known. We studied these issues in a large cohort of adult
celiac disease patients.
Methods: The prevalence of type 1 and type 2 diabetes in 1358 celiac patients was compared with the
population-based values. Furthermore, patients with celiac disease and concomitant type 1 or type 2 diabetes
and those with celiac disease only underwent comparisons of clinical and histological features and adherence
to gluten-free diet.
Results: The prevalence of type 1 diabetes (men/women) was 8.0 % /1.8 % in celiac patients and 0.7 % /0.3 % in the
population, and that of type 2 diabetes 4.3 % /2.5 % and 4.4 % /3.0 %, respectively. Celiac patients with concomitant
type 1 diabetes were younger (45 years vs 65 years and 52 years, P < 0.001) and more often screen-detected (43 % vs
13 % and 14 %, P < 0.001), had less other gastrointestinal diseases (8 % vs 40 % and 25 %, P = 0.028), more thyroidal
diseases (18 % vs 16 % and 13 %, P = 0.043) and lower dietary adherence (71 % vs 95 % and 96 %, P < 0.001) compared
with celiac patients with concomitant type 2 diabetes and patients with celiac disease only. Patients with concomitant
type 2 diabetes had more hypercholesterolemia than the other groups (8 % vs 6 % and 4 %, P = 0.024), and both
diabetes groups more hypertension (47 % and 31 % vs 15 %, P < 0.001) and coronary artery disease (29 % and 18 % vs
3 %, P < 0.001) than the patients with celiac disease only.
Conclusions: Type 1 diabetes was markedly overrepresented in celiac disease, especially in men, whereas the
prevalence of type 2 diabetes was comparable with the population. Concomitant type 1 or type 2 diabetes
predisposes celiac patients to severe co-morbidities and type 1 diabetes also to poor dietary adherence.
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Background
Celiac disease is a life-long immune-mediated disorder
characterized by gluten-triggered inflammation and
morphological damage of the small-bowel mucosa in gen-
etically susceptible individuals [1, 2]. The disease is one of
the commonest food-related disorders with a currently
estimated prevalence of 1–2 % in the Western populations
[3]. Moreover, it is overrepresented in type 1 diabetes
(DM1), which shares a mutual genetic predisposition with
CD [4]. Although this association is well established
particularly in children, the effect of concomitant DM1 on
the clinical and histological presentation in adult celiac
disease patients remains unclear. In contrast to DM1, the
non-autoimmune-mediated type 2 diabetes (DM2) is not
considered to be overrepresented in celiac disease [5]. In
fact, Kabbani and colleagues [6] have recently reported
DM2 to be even less frequent among celiac disease
patients than in the US population in general, indicating
possible protective effect. Evidently, their finding should
be confirmed in other countries. In addition, the effect of
concomitant DM2 on the presentation and natural history
of celiac disease in adult patients is scarcely studied.
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The aim of the present study was to investigate the
prevalence of DM1 and DM2 in Finnish adults with
celiac disease and to compare these figures with those in
the general population. In addition, we compared a
variety of clinical, serological and histological parameters
and dietary adherence between celiac disease patients
with and without concomitant DM1 or DM2.
Methods
Patients and study design
The study was conducted at the University of Tampere and
Tampere University Hospital. The celiac disease cohort
comprised of 1358 adults (984 women and 374 men, age at
diagnosis ≥16 years) collected from our regularly updated
research database. The patient information was gathered
from the medical records and, when inadequate, supple-
mented with personal interviews by a physician or study
nurse. Following information at celiac disease diagnosis
was collected from each subject: demographic, clinical and
histological data, blood hemoglobin and celiac disease
serology, presence of concomitant other chronic medical
conditions, family history of celiac disease, and adherence
to the gluten-free diet. The diagnosis of celiac disease was
based on the demonstration of small-bowel mucosal villous
atrophy and crypt hyperplasia in duodenal biopsies taken
upon gastroscopy [2]. After the analyses, the patients were
divided into three groups based on the presence of celiac
disease and either concomitant DM1 (DM1 group), DM2
(DM2 group), or no diabetes (CD group). The diagnoses of
DM1 and DM2 were set by the hospital physicians accord-
ing to the national guidelines [7].
The prevalence of DM1 and DM2 was compared with
that of general population utilizing the results of the
Health 2000 survey [8]. The survey consists of 7419
Finnish adults aged ≥30 years who participated on a
nationwide public health study. From these 6354
(79.7 %) underwent further examination at primary care
where the presence of self-reported diabetes was
confirmed. Next, these nationwide representative preva-
lences were compared with those found in the present
study. Due to the age limitation of the Health 2000 study
[9] only celiac disease patients aged ≥30 years were
included in this comparison (n = 1254).
The Regional Ethics Committee of the Tampere
University Hospital District approved the study protocol,
and all subjects participating to the personal interviews
gave written informed consent.
Clinical presentation, serology and adherence to gluten-
free diet
The main mode of presentation at celiac disease diagnosis
was categorized into three groups: 1. Classical gastrointes-
tinal celiac disease comprising subjects with for example
diarrhea and malabsorption; 2. non-classical presentations
such as dermatitis herpetiformis, infertility, joint pains and
neurological symptoms; and 3. apparently silent/asymp-
tomatic subjects detected by screening in at-risk groups.
From the concomitant chronic diseases, particular
attention was paid to the presence of autoimmune and
gastrointestinal disorders, osteoporosis or osteopenia,
asthma, malignancies, hypercholesterolemia and cardiovas-
cular diseases. Anemia at diagnosis was defined as a
hemoglobin value <13.4 g/dL in men and <11.7 g/dL in
women [9].
Adherence to the gluten-free diet was considered
“strict” if the patient reported no dietary lapses. A few
minor lapses less than once per a month was regarded
as “occasional lapses”, and lapses more often than that
as “no gluten-free diet”. Furthermore, the strictness of
the diet was estimated on the basis of the positivity (titer
1:≥5) to endomysial antibodies (EmA) after a minimum
of one year on gluten-free diet. The antibodies were
measured by a well-validated in-house test that uses
human umbilical cord as substrate [10].
Small-bowel mucosal histology
In our settings 4–6 duodenal biopsies are routinely
taken in each case with celiac disease suspicion. The
specimens are further referred to the hospital
pathology department where the degree of small-
bowel mucosal damage is evaluated from well-
orientated biopsy cuttings [11]. Here the severity of
the mucosal lesion was graded to partial, subtotal or
total villous atrophy based on the original pathology
report. Further, the presence of possible repeat biopsy
and the degree of mucosal recovery on a gluten-free
diet were recorded.
Availability of data and materials
All available raw data will not be shared as this contains
confidential patient information. All other relevant study
data are presented in the Tables.
Statistics
Variables are presented either as percentages or medians
with range. Categorical variables were analyzed using chi-
square and Fisher’s exact test, and numeric variables using
the Kruskal –Wallis test. Logistic regression was used to
adjust for gender, current age and age at the celiac disease
diagnosis when appropriate. These results are presented in
the Table 2 as “Crude” referring to the results of chi-
square or Fisher’s exact test and as “Adjusted” referring to
those of logistic regression. P value ≤ 0.05 was considered
significant. All analyses were executed using Statistical
Package for the Social Sciences version 20 (IBM, Armonk,
NY, USA).
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Results
Prevalence of concomitant type 1 and type 2 diabetes in
celiac disease
Of the all 1358 celiac disease patients, 51 (3.8 %) had a
concomitant DM1 and 38 (2.8 %) DM2. The correspond-
ing figures in those aged ≥30 years (n = 1254) were 44
(3.5 %) and 38 (3.0 %), respectively. In this age group, the
prevalence of DM1 was markedly higher in celiac patients
than in the general population (Table 1). In men, DM1
was particularly overrepresented in celiac patients aged
30–64 years, and somewhat less in those aged over 65
years. In women DM1 was roughly five times more
common in celiac disease than in the population in
patients aged ≥30 years. In contrast to DM1, DM2 was
slightly underrepresented in celiac men ≥65 years, and
there was no marked difference between celiac disease
and population in younger men or women (Table 1).
Demographic data and clinical features at celiac disease
diagnosis
The DM1 group comprised lower proportion of women
than the DM2 group and CD groups. The median age at
celiac disease diagnosis was higher in DM2 group than
in the two other groups (Table 2). DM1 patients had less
abdominal symptoms and malabsorption, and they were
more often detected by serologic screening than the
subjects in the DM2 and CD groups. There were no
significant differences between the groups in the severity
of histological damage and hemoglobin levels or pres-
ence of anemia, percentages of celiac disease in relatives
and positivity to EmA (Table 2).
Concomitant DM1 or DM2 increased the risk of
coronary artery disease and hypertension (Table 3).
Furthermore, patients in the DM1 group had more
thyroidal diseases and less other gastrointestinal diseases
except celiac disease, and those in the DM2 group more
hypercholesterolemia compared with the two other
groups. There were no significant differences in the
prevalence of osteoporosis, asthma or malignancies
between the groups (Table 3).
Dietary interview disclosed that the adherence to
gluten-free diet was not as good in the DM1 group as in
the DM2 and CD groups (Table 3). This was also
supported by the higher prevalence of EmA positivity in
the DM1 group while on dietary treatment.
Histological recovery on a gluten-free diet
A repeat biopsy on a gluten-free diet had been taken
after a median of one year (range 0.5–41 years) in 51 %
of the subjects in the DM1 group, 47 % in the DM2
group and 62 % in the CD group. Altogether 65 % of the
patients in the DM1 group were found to have fully
recovered small-intestinal mucosa, 12 % had partial
villous atrophy and 12 % subtotal/total villous atrophy
on diet; the corresponding figures in the DM2 group
were 44, 50 and 6 % and in the CD group 71, 24 and
5 %, respectively (p = 0.059).
Discussion
A novel finding of the present study is that DM1 is
markedly overrepresented especially in men with celiac
disease, whereas the prevalence of DM2 was practically
similar to that of the Finnish population in general.
Furthermore, concomitant DM1 or DM2 predispose
celiac disease patients to severe comorbidities, and DM1
also to lower adherence to the gluten-free diet.
Here the overall prevalence of DM1 among celiac
patients over 30 years of age was 3.8 %. This is signifi-
cant overrepresentation compared to the population
even in Finland where the incidence of DM1 is one of
the highest in the world [12]. In contrast to our study,
the great majority of the previous studies investigating
the association between celiac disease and DM1 have
been conducted in children [13, 14] of whom the charac-
teristics of the concomitant diseases could be different.
In addition, opposed to our design, the earlier studies
have mainly investigated the prevalence of celiac disease
Table 1 Prevalence of type 1 and type 2 diabetes in celiac diseasea and general populationb
DM1 DM2
Celiac disease General population Celiac disease General population
Age Sex % % % %
All ≥30 M 8.0 0.7 4.3 4.4
F 1.8 0.3 2.5 3.0
Subgroups 30–64 M 10.0 0.7 3.8 3.0
F 1.9 0.4 1.2 1.5
≥ 65 M 2.2 0.8 5.6 9.4
F 1.1 0.2 7.9 8.9
DM1, type 1 diabetes; DM 2, type 2 diabetes
aStudy patients with celiac disease aged 30 years or more (n = 1254)
bThe Health 2000 Survey
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Table 2 Clinical, serological and histological characteristics of celiac disease in 1358 patientsa
DM1 DM2 No diabetes
n = 51 n = 38 n = 1269 P value
Females, % 39 61 74 <0.001
Current age, median (range), yr 45 (18–71) 65 (45–83) 52 (20–92) <0.001
Age at dg of CD, median (range), yr 38 (2–70) 53 (26–76) 42 (2–89) <0.001
Mode of presentation at dg, % <0.001
Gastrointestinal symptoms 35 50 54
Malabsorption 8 24 17
Extra-intestinal symptomsb 14 13 16
Risk-group screeningc 43 13 14
Hb at dg, median (range), g/l 131 (114–152) 134 (112–165) 128 (39–174) 0.272
Anemia at dg, % 20 26 27 0.515
CD in relatives, % 58 61 60 0.964
Positive EmA at dg, % 100 91 88 0.431
Degree of villous atrophy, % 0.433
Total 42 36 31
Subtotal 29 50 38
Partial 29 14 31
DM1, type 1 diabetes; DM2, type 2 diabetes
Hb hemoglobin, EmA endomysial antibodies
aCeliac disease patients with or without concomitant DM1 or DM2
bDermatitis herpetiformis, infertility, arthralgia or arthritis, osteoporosis, dental enamel defects, polyneuropathy, hypertransaminasemia, aphtous stomatitis
cDM1, family history for celiac disease, autoimmune thyroid disease, Sjögren’s syndrome
Table 3 Presence of co-morbidities and adherence to the gluten-free diet (GFD) in 1358 celiac disease patientsa
DM1 DM2 No diabetes P value
n = 51 n = 38 n = 1269 Crudeb Adjustedc
Co-morbidity, %
Autoimmune thyroidal diseases 18 16 13 0.538 0.043
Coronary artery disease 18 29 3 <0.001 <0.001
Hypertension 31 47 15 <0.001 <0.001
Hypercholesterolemia 8 24 6 0.001 0.024
Osteoporosis or osteopenia 4 11 13 0.165 0.225
Asthma 4 13 7 0.265 0.456
Malignancyd 4 5 4 0.815 0.873
Gastrointestinal diseasee 8 40 25 0.002 0.028
GFD, median (range), yr 6 (1–36) 7 (1–32) 8 (1–59) 0.935
Strictness of GFD, % <0.001
Strict 71 95 96
Occasional gluten 22 5 4
No diet 6 0 0
Positive EmA on GFD, % 30 9 6 <0.001 <0.001
DM1, type 1 diabetes; DM2, type 2 diabetes
EmA endomysial antibodies
aCeliac disease patients with or without concomitant DM1 or DM2
bChi-square and Fisher’s exact test
cAdjusted for current age, age at celiac disease diagnosis and gender by logistic regression
dCancer of breast, prostate, colon, small intestine, uterus, thyroid gland, ovary, lip, spine; sarcoma
eLactose intolerance, food allergy, gastroesophageal reflux disease, Barrett’s esophagus, gastric ulcer, diverticulosis, Crohn’s disease, irritable bowel syndrome,
cholelithiasis, cholecystitis, chronic gastritis, diverticulitis, undefined colitis, chronic hepatitis
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in diabetic patients [15, 16]. Another interesting finding
of the present study was the substantially higher preva-
lence of DM1 among men with celiac disease (8.0 %)
compared with the corresponding women (1.8 %). Even
though, unlike most other autoimmune diseases, DM1 is
known to be in general more common in men [17, 18],
this aspect has not been studied in celiac patients before,
and the gender difference was surprisingly large.
Interestingly, it has been observed that the male-to-
female ratio of DM1 ratio differs between age groups
[17], and also that it is higher in countries where DM1 is
common [18]. The latter might partly explain the high
number of DM1 men in our study population, but
further studies are needed to fully explain these gender
discrepancies. The prevalence of DM1 was also almost
five times higher in celiac disease men aged 30–64 years
compared with men being 65 years or more. The lower
DM1 prevalence among older celiac patients could be
due to increased mortality in DM1 [16]. Accordingly, it
has been shown that co-existing celiac disease of more
than 15 years increases the risk of death in DM1 patients
compared to patients with only DM1 [19, 20]. The
higher prevalence of DM1 in younger men here could
also be partly due to increasing incidence of DM1 over
time at population level [21].
The overall prevalence of DM2 in our celiac disease
cohort was at the same level as in Finnish adults in
general. Further, the only noticeable difference in the
subgroup comparisons was the lower prevalence of DM2
in celiac men aged ≥65 years compared with the popula-
tion. Our results differ from those observed by Kabbani
and colleagues, who recently found the prevalence of
DM2 to be more than three times lower in celiac disease
patients than in the US population [6]. One explanation
for the discrepant results could be differences in the
disease presentation, as in Finland celiac patients have in
general rather short diagnostic delay and mild clinical
picture, whereas in US patients the classical malabsorp-
tive disease with weight loss is still common [22, 23].
Finnish patients are usually normal weight or even over-
weight at diagnosis and it might be argued that they thus
have “normal” risk for DM2 [24]. However, in the US
study the protective effect of celiac disease was observed
even after controlling for malabsorption, symptoms and
BMI, indicating that there are other reasons for the
different results. Another possibly affecting factor is the
selection of control group and the overall prevalence of
DM2 in the population. For example, the US study com-
prised two separate control groups, including age-, sex-,
and ethnicity-matched controls and subjects of National
Health and Nutrition Examination Survey [25]. The
prevalences of DM2 in these groups were 9.6 % and
9.8 %, respectively, while in our control group it was
only 4.4 % in men and 3.0 % in women. Obviously there
can also be differences in genetics, diagnostic criteria of
DM2 and lifestyle, but the true role of these factors
remains to be solved in future studies.
The clinical presentation of celiac disease was quite
similar in three groups, the only significant difference
being the markedly higher rate of screen-detected
patients in the DM1 group. This is not surprising, as in
Finland the increased risk of celiac disease in DM1
patients is well-known among physicians, and thus they
are screened at low threshold [26]. Subjects in DM1
group also had their celiac disease diagnosed at younger
age, which might similarly be due to active screening. As
expected, the presence of both concomitant DM1 and
DM2 significantly increased the prevalence of coronary
artery disease and hypertension in celiac disease patients
compared with those being non-diabetic. This is in
agreement with previous finding by Pitocco and co-
workers that concomitant DM1 increases the risk of
sub-clinical atherosclerosis in celiac disease [27]. How-
ever, since we did not have specific non-celiac DM1 or
DM2 control groups, it remains unclear whether celiac
disease truly has an additional effect to the risk of
cardiovascular complications, or whether their increased
prevalence are caused solely by the concomitant diabetes.
The prevalence of thyroidal diseases was also higher in
celiac patients with DM1 compared with other groups
even after controlling for age and gender. This was also
quite expected, as the association of autoimmune thyroi-
dal diseases with both DM1 and celiac disease has been
well-established [28, 29]. These disease associations are
important to remember when treating patients with
simultaneous celiac disease and diabetes.
Adherence to the gluten-free diet was significantly
lower among celiac disease patients with a concomitant
DM1 compared with the two other study groups. This
result from interviews was further confirmed by the
higher proportion of EmA-positivity in the DM1 group
while on the diet. The lower adherence is in line with
previous studies where the dietary adherence has also
been relatively low among patients with the double-
diagnosis of CD and DM1 [30, 31]. Celiac disease
patients with a concomitant DM1 may find it more diffi-
cult to cope with the demanding diet while already
needing to concentrate to continuous daily glucose level
monitoring, carbohydrate calculation and insulin dosing.
Moreover, as seen in here and previously [32], celiac pa-
tients with concomitant DM1 are often screen-detected
and therefore have possibly only mild or no apparent
symptoms, which might further decrease the motivation
to adhere to expensive and socially restrictive gluten-free
diet. There is no reason to believe that the maintenance
of strict diet is less important in celiac patients with
diabetes that in celiac disease altogether. These patients
may need individualized support for the dietary treatment,
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and also careful follow-up to ensure coping with the
increased disease burden. Accordingly, we have earlier
shown that rigorous dietary counselling in patients with
celiac disease and concomitant DM1 improves the dietary
adherence to gluten-free diet [30]. Interestingly, despite
the poorer adherence, DM1 patients did not show signifi-
cantly inferior mucosal recovery after a median of one
year on a gluten-free diet. Nevertheless, they had the
highest percentage of subtotal or total villous atrophy
while on diet. Furthermore, notwithstanding the appar-
ently equal dietary adherence, there was also a trend for
slower histological recovery among subjects in the DM2
group compared with those in the CD group. Further
studies are needed to establish whether concomitant dia-
betes predisposes celiac disease patients to slower mucosal
recovery or even persistent villous atrophy on a gluten-
free diet.
Major strengths of the present study are the high
number of biopsy-proven celiac disease patients with
heterogeneous clinical presentation and the representa-
tive control population acquired from a nationwide
public health study. In addition, we were able to gather
abundant clinical and histological information from each
patient. Major limitations were the retrospective study
design and the lack of specific information on the
disease profile of DM1 and DM2. Further, the non-celiac
diabetic control groups would have been needed to
estimate the role of concomitant celiac disease in the
increased risk of cardiovascular complications. The fact
that repeat biopsy on a gluten-free diet was taken less
often from DM1 and DM2 patients may cause selection
bias. It would have also been very interesting to see
whether there are differences between the groups in
overall mortality, but unfortunately we did not have this
data systemically collected. In any case, the cross-
sectional study design and a relatively short follow-up
time in most of the patients might have made these
results somewhat unreliable. Finally, there was no exact
data when the diabetes diagnosis was made with respect
of celiac disease diagnosis.
Conclusions
To conclude, in Finnish adult population, DM1 was
significantly overrepresented in celiac disease, whereas
the prevalence of concomitant DM2 was at the same
level as in the population. Clinicians should be aware
that that the double diagnosis of celiac disease and
either DM2 or DM1 predisposes the patients to
severe co-morbidities. Celiac disease patients with
concomitant DM1 have increased risk for dietary
lapses and possibly also to poorer histological recov-
ery, and require therefore specifically-tailored support
and careful follow-up.
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